The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
BEOVU (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
BEOVU
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
brolucizumab
Registration type
EOI
Indication
BEOVU is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (AMD),
- Diabetic macular oedema (DME).